Danazol therapy for cyclic thrombocytopenia
Cyclic thrombocytopenia is a rare disease characterized by cyclic oscillations of platelet counts from very low to normal or higher. Severe hemorrhage may occur during the thrombocytopenic phase. To date, treatments for this disorder have been disappointing. Its pathophysiology is unknown. We report...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 1991-02, Vol.36 (2), p.140-143 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 143 |
|---|---|
| container_issue | 2 |
| container_start_page | 140 |
| container_title | American journal of hematology |
| container_volume | 36 |
| creator | Rocha, Rafael Horstman, Lawrence Ahn, Yeon S. Mylvaganam, Ravindra Harrington, William J. |
| description | Cyclic thrombocytopenia is a rare disease characterized by cyclic oscillations of platelet counts from very low to normal or higher. Severe hemorrhage may occur during the thrombocytopenic phase. To date, treatments for this disorder have been disappointing. Its pathophysiology is unknown. We report a successful outcome using danazol therapy.
It can be argued that the long‐term outcome was due to spontaneous remission. However, significant improvement was noted from the outset of danazol therapy, and further improvement with long‐term therapy, as seen in the response of chronic ITP to danazol therapy. Danazol may offer lasting benefit in cyclic thrombocytopenia. |
| doi_str_mv | 10.1002/ajh.2830360213 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80500030</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80500030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4653-8a12697c840b29984fb900aada0d41aa804185088fd3612672f21b0c70700ba43</originalsourceid><addsrcrecordid>eNqFUD1PwzAQtRColMLKhtQFFpRydpzEHqvyUVAlFpiti-OoqZI42K1Q-PUYNaJsTHe69-7du0fIJYUZBWB3uFnPmIghToHR-IiMKcg0EmnCjsk4TGnoQZ6SM-83AJRyASMyYkAZpHxMbu-xxS9bT7dr47Drp6V1U93rutJh5GyTW91vbWfaCs_JSYm1NxdDnZD3x4e3xTJavT49L-arSPM0iSOBlKUy04JDzqQUvMwlAGKBUHCKKIBTkYAQZRHssTRjJaM56AwygBx5PCE3e93O2Y-d8VvVVF6busbW2J1XAhIACC9PyGxP1M5670ypOlc16HpFQf2ko0I66pBOWLgalHd5Y4pf-hBHwK8HHL3GunTY6sofVGWWgBQy8OSe91nVpv_nqpq_LP94-AbTJXsI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80500030</pqid></control><display><type>article</type><title>Danazol therapy for cyclic thrombocytopenia</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Rocha, Rafael ; Horstman, Lawrence ; Ahn, Yeon S. ; Mylvaganam, Ravindra ; Harrington, William J.</creator><creatorcontrib>Rocha, Rafael ; Horstman, Lawrence ; Ahn, Yeon S. ; Mylvaganam, Ravindra ; Harrington, William J.</creatorcontrib><description>Cyclic thrombocytopenia is a rare disease characterized by cyclic oscillations of platelet counts from very low to normal or higher. Severe hemorrhage may occur during the thrombocytopenic phase. To date, treatments for this disorder have been disappointing. Its pathophysiology is unknown. We report a successful outcome using danazol therapy.
It can be argued that the long‐term outcome was due to spontaneous remission. However, significant improvement was noted from the outset of danazol therapy, and further improvement with long‐term therapy, as seen in the response of chronic ITP to danazol therapy. Danazol may offer lasting benefit in cyclic thrombocytopenia.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.2830360213</identifier><identifier>PMID: 2012064</identifier><identifier>CODEN: AJHEDD</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Autoimmune Diseases - blood ; Autoimmune Diseases - drug therapy ; autoimmune thrombocytopenia ; Biological and medical sciences ; Blood Platelets - chemistry ; Blood. Blood coagulation. Reticuloendothelial system ; cyclic oscillations ; Danazol - therapeutic use ; Female ; Humans ; Immunoglobulin G - analysis ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Platelet Count ; platelet counts ; Thrombocytopenia - blood ; Thrombocytopenia - drug therapy ; Time Factors</subject><ispartof>American journal of hematology, 1991-02, Vol.36 (2), p.140-143</ispartof><rights>Copyright © 1991 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4653-8a12697c840b29984fb900aada0d41aa804185088fd3612672f21b0c70700ba43</citedby><cites>FETCH-LOGICAL-c4653-8a12697c840b29984fb900aada0d41aa804185088fd3612672f21b0c70700ba43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.2830360213$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.2830360213$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19750989$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2012064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rocha, Rafael</creatorcontrib><creatorcontrib>Horstman, Lawrence</creatorcontrib><creatorcontrib>Ahn, Yeon S.</creatorcontrib><creatorcontrib>Mylvaganam, Ravindra</creatorcontrib><creatorcontrib>Harrington, William J.</creatorcontrib><title>Danazol therapy for cyclic thrombocytopenia</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>Cyclic thrombocytopenia is a rare disease characterized by cyclic oscillations of platelet counts from very low to normal or higher. Severe hemorrhage may occur during the thrombocytopenic phase. To date, treatments for this disorder have been disappointing. Its pathophysiology is unknown. We report a successful outcome using danazol therapy.
It can be argued that the long‐term outcome was due to spontaneous remission. However, significant improvement was noted from the outset of danazol therapy, and further improvement with long‐term therapy, as seen in the response of chronic ITP to danazol therapy. Danazol may offer lasting benefit in cyclic thrombocytopenia.</description><subject>Autoimmune Diseases - blood</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>autoimmune thrombocytopenia</subject><subject>Biological and medical sciences</subject><subject>Blood Platelets - chemistry</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>cyclic oscillations</subject><subject>Danazol - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G - analysis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Count</subject><subject>platelet counts</subject><subject>Thrombocytopenia - blood</subject><subject>Thrombocytopenia - drug therapy</subject><subject>Time Factors</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUD1PwzAQtRColMLKhtQFFpRydpzEHqvyUVAlFpiti-OoqZI42K1Q-PUYNaJsTHe69-7du0fIJYUZBWB3uFnPmIghToHR-IiMKcg0EmnCjsk4TGnoQZ6SM-83AJRyASMyYkAZpHxMbu-xxS9bT7dr47Drp6V1U93rutJh5GyTW91vbWfaCs_JSYm1NxdDnZD3x4e3xTJavT49L-arSPM0iSOBlKUy04JDzqQUvMwlAGKBUHCKKIBTkYAQZRHssTRjJaM56AwygBx5PCE3e93O2Y-d8VvVVF6busbW2J1XAhIACC9PyGxP1M5670ypOlc16HpFQf2ko0I66pBOWLgalHd5Y4pf-hBHwK8HHL3GunTY6sofVGWWgBQy8OSe91nVpv_nqpq_LP94-AbTJXsI</recordid><startdate>199102</startdate><enddate>199102</enddate><creator>Rocha, Rafael</creator><creator>Horstman, Lawrence</creator><creator>Ahn, Yeon S.</creator><creator>Mylvaganam, Ravindra</creator><creator>Harrington, William J.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199102</creationdate><title>Danazol therapy for cyclic thrombocytopenia</title><author>Rocha, Rafael ; Horstman, Lawrence ; Ahn, Yeon S. ; Mylvaganam, Ravindra ; Harrington, William J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4653-8a12697c840b29984fb900aada0d41aa804185088fd3612672f21b0c70700ba43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Autoimmune Diseases - blood</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>autoimmune thrombocytopenia</topic><topic>Biological and medical sciences</topic><topic>Blood Platelets - chemistry</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>cyclic oscillations</topic><topic>Danazol - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G - analysis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Count</topic><topic>platelet counts</topic><topic>Thrombocytopenia - blood</topic><topic>Thrombocytopenia - drug therapy</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rocha, Rafael</creatorcontrib><creatorcontrib>Horstman, Lawrence</creatorcontrib><creatorcontrib>Ahn, Yeon S.</creatorcontrib><creatorcontrib>Mylvaganam, Ravindra</creatorcontrib><creatorcontrib>Harrington, William J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rocha, Rafael</au><au>Horstman, Lawrence</au><au>Ahn, Yeon S.</au><au>Mylvaganam, Ravindra</au><au>Harrington, William J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Danazol therapy for cyclic thrombocytopenia</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>1991-02</date><risdate>1991</risdate><volume>36</volume><issue>2</issue><spage>140</spage><epage>143</epage><pages>140-143</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><coden>AJHEDD</coden><abstract>Cyclic thrombocytopenia is a rare disease characterized by cyclic oscillations of platelet counts from very low to normal or higher. Severe hemorrhage may occur during the thrombocytopenic phase. To date, treatments for this disorder have been disappointing. Its pathophysiology is unknown. We report a successful outcome using danazol therapy.
It can be argued that the long‐term outcome was due to spontaneous remission. However, significant improvement was noted from the outset of danazol therapy, and further improvement with long‐term therapy, as seen in the response of chronic ITP to danazol therapy. Danazol may offer lasting benefit in cyclic thrombocytopenia.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>2012064</pmid><doi>10.1002/ajh.2830360213</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 1991-02, Vol.36 (2), p.140-143 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80500030 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Autoimmune Diseases - blood Autoimmune Diseases - drug therapy autoimmune thrombocytopenia Biological and medical sciences Blood Platelets - chemistry Blood. Blood coagulation. Reticuloendothelial system cyclic oscillations Danazol - therapeutic use Female Humans Immunoglobulin G - analysis Medical sciences Middle Aged Pharmacology. Drug treatments Platelet Count platelet counts Thrombocytopenia - blood Thrombocytopenia - drug therapy Time Factors |
| title | Danazol therapy for cyclic thrombocytopenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A50%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Danazol%20therapy%20for%20cyclic%20thrombocytopenia&rft.jtitle=American%20journal%20of%20hematology&rft.au=Rocha,%20Rafael&rft.date=1991-02&rft.volume=36&rft.issue=2&rft.spage=140&rft.epage=143&rft.pages=140-143&rft.issn=0361-8609&rft.eissn=1096-8652&rft.coden=AJHEDD&rft_id=info:doi/10.1002/ajh.2830360213&rft_dat=%3Cproquest_cross%3E80500030%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80500030&rft_id=info:pmid/2012064&rfr_iscdi=true |